Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2013

01-01-2013 | Epidemiology

Impact of breast cancer on anti-mullerian hormone levels in young women

Authors: H. I. Su, S. W. Flatt, L. Natarajan, A. DeMichele, A. Z. Steiner

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Abstract

Young women with breast cancer face treatments that impair ovarian function, but it is not known if malignancy itself impacts ovarian reserve. As more breast cancer patients consider future fertility, it is important to determine if ovarian reserve is impacted by cancer, prior to any therapeutic intervention. A cross-sectional study was conducted comparing if ovarian reserve, as measured by anti-mullerian hormone (AMH), follicle stimulating hormone (FSH), and inhibin B (inhB), differed between 108 women with newly diagnosed breast cancer and 99 healthy women without breast cancer. Breast cancer participants were ages 28–44 and were recruited from two clinical breast programs. Healthy women ages 30–44 without a history of infertility were recruited from gynecology clinics and the community. The median age (interquartile range) was 40.2(5.5) years for breast cancer participants and 33.0(4.6) years for healthy controls. The unadjusted geometric mean AMH levels (SD) for breast cancer participants and controls were 0.66(3.6) and 1.1(2.9) ng/mL, respectively. Adjusting for age, body mass index, gravidity, race, menstrual pattern, and smoking, mean AMH levels were not significantly different between breast cancer participants and healthy controls (0.85 vs. 0.76 ng/mL, p = 0.60). FSH and inhB levels did not differ by breast cancer status. In exploratory analysis, the association between AMH and breast cancer status differed by age (p-interaction = 0.02). AMH may be lower with breast cancer status in women older than 37. In younger women, AMH levels did not differ significantly by breast cancer status. Among the youngest of breast cancer patients, ovarian reserve as measured by AMH, FSH, and inhibin B did not differ significantly from healthy women of similar age. In older breast cancer patients, ovarian reserve may be adversely impacted by cancer status. These findings support the potential success and need for fertility preservation strategies prior to institution of cancer treatment.
Literature
1.
2.
Warne GL, Fairley KF, Hobbs JB, Martin FI (1973) Cyclophosphamide-induced ovarian failure. N Engl J Med 289(22):1159–1162PubMedCrossRef
3.
Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583–2592PubMedCrossRef
4.
Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR, DeMichele A (2010) Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116(3):592–599PubMedCrossRef
5.
Partridge AH, Gelber S, Peppercorn J, Ginsburg E, Sampson E, Rosenberg R, Przypyszny M, Winer EP (2008) Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer 8(1):65–69PubMedCrossRef
6.
Schover LR (2008) Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 26(5):753–758PubMedCrossRef
7.
Bahadur G, Ozturk O, Muneer A, Wafa R, Ashraf A, Jaman N, Patel S, Oyede AW, Ralph DJ (2005) Semen quality before and after gonadotoxic treatment. Hum Reprod 20(3):774–781PubMedCrossRef
8.
Bahadur G, Ling KL, Hart R, Ralph D, Wafa R, Ashraf A, Jaman N, Mahmud S, Oyede AW (2002) Semen quality and cryopreservation in adolescent cancer patients. Hum Reprod 17(12):3157–3161PubMedCrossRef
9.
Su HI (2010) Measuring ovarian function in young cancer survivors. Minerva Endocrinol 35(4):259–270PubMed
10.
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB (2006) A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12(6):685–718PubMedCrossRef
11.
Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ (2007) Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 87(4):764–775PubMedCrossRef
12.
La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS (2009) Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod 24(9):2264–2275PubMedCrossRef
13.
Freeman EW, Sammel MD, Lin H, Gracia CR (2012) Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 97(5):1673–1680PubMedCrossRef
14.
La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A (2010) Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16(2):113–130PubMedCrossRef
15.
Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F (2009) Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril 91(4 Suppl):1476–1478PubMedCrossRef
16.
Quintero RB, Helmer A, Huang JQ, Westphal LM (2010) Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril 93(3):865–868PubMedCrossRef
17.
Robertson AD, Missmer SA, Ginsburg ES (2011) Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril 95(2):588–591PubMedCrossRef
18.
Pal L, Leykin L, Schifren JL, Isaacson KB, Chang YC, Nikruil N, Chen Z, Toth TL (1998) Malignancy may adversely influence the quality and behaviour of oocytes. Hum Reprod 13(7):1837–1840PubMedCrossRef
19.
Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, Garcia-Velasco JA (2012) Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 97(4):930–934PubMedCrossRef
20.
Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd (2007) Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 87(1):101–106PubMedCrossRef
21.
Efron BT, Tibshirani RJ (1994) An introduction to the bootstrap. CRC Press, Boca Raton
22.
Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, Baird DD (2010) Antimullerian hormone as a predictor of natural fecundability in women aged 30–42 years. Obstet Gynecol 117(4):798–804CrossRef
23.
Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T (2011) Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril 96(1):122–125PubMedCrossRef
24.
Moria A, Das M, Shehata F, Holzer H, Son WY, Tulandi T (2011) Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment. Fertil Steril 95(5):1621–1623PubMedCrossRef
25.
Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, Hershman DL (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9):2099–2105PubMed
26.
Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, Henes M (2012) Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma-evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril 98(1):141–144PubMedCrossRef
27.
Plante BJ, Cooper GS, Baird DD, Steiner AZ (2010) The impact of smoking on antimullerian hormone levels in women aged 38–50 years. Menopause 17(3):571–576PubMed
28.
Hehenkamp WJ, Volkers NA, Broekmans FJ, de Jong FH, Themmen AP, Birnie E, Reekers JA, Ankum WM (2007) Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 22(7):1996–2005PubMedCrossRef
29.
La Marca A, Stabile G, Artenisio AC, Volpe A (2006) Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21(12):3103–3107PubMedCrossRef
30.
Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y (2007) Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 22(7):1837–1840PubMedCrossRef
31.
Li HW, Anderson RA, Yeung WS, Ho PC, Ng EH (2011) Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea. Fertil Steril 96(3):774–779PubMedCrossRef
32.
Nelson SM, La Marca A (2012) The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 23(4):411–420CrossRef
33.
Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE (2010) Development of a second generation anti-Mullerian hormone (AMH) ELISA. J Immunol Methods 362(1–2):51–59PubMedCrossRef
34.
Lee JR, Kim SH, Jee BC, Suh CS, Kim KC, Moon SY (2011) Antimullerian hormone as a predictor of controlled ovarian hyperstimulation outcome: comparison of two commercial immunoassay kits. Fertil Steril 95(8):2602–2604PubMedCrossRef
35.
Streuli I, Fraisse T, Chapron C, Bijaoui G, Bischof P, de Ziegler D (2009) Clinical uses of anti-Mullerian hormone assays: pitfalls and promises. Fertil Steril 91(1):226–230PubMedCrossRef
36.
Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D (2007) Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 375(1–2):162–164PubMedCrossRef
Metadata
Title
Impact of breast cancer on anti-mullerian hormone levels in young women
Authors
H. I. Su
S. W. Flatt
L. Natarajan
A. DeMichele
A. Z. Steiner
Publication date
01-01-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2361-5

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue

Epidemiology

One-day core needle biopsy in a breast clinic: 4 years experience

Review

Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis

Preclinical Study

Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features

Letter to the Editor

Unincluded subjects need to be included for concerning the real association between TNFa−308 G/A polymorphism and cancer susceptibility

Clinical Trial

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

Preclinical Study

Differential expression of immune-related markers in breast cancer by molecular phenotypes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits